Citations

Clear

3042 citation(s) found for "Kumar, S".

Moderate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga, Francisco , Díaz, Luis Antonio , Dunn, Winston , Muñoz, Karen E., Caldentey, Vicente, Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Malhi, Gurpreet, Ahmed, Adan, Homsi, Hoomam , Abid, Zinia, Echavarría, Victor, Poca, María , Cuyàs, Berta , Ventura‐Cots, Meritxell , Higuera‐de‐la‐Tijera, Fátima , Ayala-Valverde, María , Pérez, Diego , Gómez, Jaime , Abraldes, Juan, Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García–Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Chacko, Kristina R. , Yaquich, Pamela, Toro, Luis, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Ramirez-Cadiz, Carolina , Poca, Maria , Soriano, German , Cuyas, Berta , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Ayala-Valverde, María , Jalal, Prasun K , Skladaný, Lubomir , Havaj, Daniel J , Chacko, Kristina R , Restrepo, Juan C , Shah, Vijay, Arrese, Marco , Kamath, Patrick S , Bataller, Ramon A , Díaz, Luis A , Elfeki, Mohamed A , Dunn, Winston , Echavaría, Victor , Muñoz, Karen, Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Ahmed, Adan, Abid, Zinia, Cabezas, Joaquín , Abraldeṣ, Juan G. , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology Communications | March 28, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1097/hc9.0000000000000673 | PMID 40131003 Get It

Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize in-depth patients with moderate AH (mAH), including the performance of mortality scoring systems, key prognostic factors, and survival over time. Methods: A multicenter retrospective cohort study (2009–2019) included patients with mAH (MELD score ≤20 at admission). Cox regression and receiver operating characteristic curves with AUC were used for analysis. Results: We included 1845 patients with AH (20 centers, 8 countries) between 2009 and 2019. mAH was defined as a MELD score ≤20 at admission. Twenty-four percent met the criteria for an mAH episode. Patients with mAH tend to be older and have a higher proportion of females, with a median MELD of 17 (15–19), Maddrey discriminant function (mDF) of 33 (22–40), the trajectory of serum bilirubin of 0.83 (0.60–1.21), and neutrophil-to-lymphocyte ratio (NLR) of 5 (2.96–8.60). The primary causes of death in mAH included multiple organ failure (34.1%) and infections (16.6%). The cumulative survival rates at 30, 90, and 180 days were 94.3%, 90.4%, and 88.2%, respectively. In multivariable analysis, age was the only significant predictor of 30-day mortality (HR 1.49, 95% CI: 1.27–1.76, p <0.001). Mortality prediction models showed poor performance, with AUC for MELD (0.671), mDF (0.726), trajectory of serum bilirubin (0.733), and NLR (0.697). Conclusions: Patients with moderate AH exhibited a mortality of 11.8% at 6 months, primarily driven by multiple organ failure and infections. These patients also exhibit a different clinical profile compared to those with sAH. Tailored models and therapeutic strategies are needed to improve long-term outcomes in mAH.
Systemic antitumor immune response of doped yttria nanoscintillators under low-dose x-ray irradiation
Sahin, Onur , Mackeyev, Yuri , Vijay, Geraldine V. , Roy, Soumyabrata , Ashokkumar, Meiyazhagan , Zahra, Yasmin , Tezcan, Okan , Gonzalez, Valeria , Abousaida, Belal , Wagner, Holden R. , FERNANDES, P. S. , Mowzoon-Mogharrabi, Riaz , Venkatesulu, Bhanu Prasad , Hsieh, Cheng‐En , Kim, Joseph Byung-Kyu, Raghuram, Subhiksha, Zhang, Xiang , Miller, Kristen A. , Gao, Guanhui , Cho, Sang Hyun , Papineni, Rao V. , Ajayan, Pulickel M., Krishnan, Sunil , Meiyazhagan, Ashokkumar , Fernandes, Pearl , Kim, Joseph B K, Papineni, Rao V L , Krishnan, Sunil , Hsieh, Rodney Cheng-En , Gonzalez, Valeria V , Mackeyev, Yuri , Mowzoon-Mogharrabi, Riaz , Singh, Pankaj Kumar , Ajayan, Pulickel M.

Mayo Clinic

Science Advances | March 26, 2025 | Volume: 11 | Issue: 13 | Pages: No page available

10.1126/sciadv.adr4008 | PMID 40138411 Get It

Inadequate light penetration in tissues restricts photodynamic therapy to treating only superficial tumors. To enable x-ray–excited photodynamic therapy (XPDT) that targets deep-seated tumors, we synthesized a nanoscintillator-photosensitizer complex containing 5% Eu-doped Y 2 O 3 fluorescing at 611 nanometers and decorated with SiO 2 containing the scintillation-coupled photosensitizer methylene blue and a polyethylene glycol coating [PEGylated Y 2 O 3 :Eu@SiO 2 -methylene blue (pYSM)]. When irradiated, pYSMs generate singlet oxygen species in vitro, causing cytotoxicity with hallmarks of immunogenic cell death (calreticulin translocation to the cell membrane). Intravenously administered pYSMs home passively to pancreatic tumor xenografts and, upon 10 gray irradiation, cause significant tumor regression ( P < 0.01). On combining XPDT with anti-PD1 immunotherapy, a distant nonirradiated tumor also regresses via an increase in intratumoral activated CD8 + cytotoxic T cells. Collectively, we advance a systemically delivered XPDT strategy that mediates an antitumor effect in both irradiated and nonirradiated (abscopal) tumors when coupled with immunotherapy, converting an immunologically “cold” tumor to an immunologically “hot” tumor.
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
Sisk, Bryan A. , Eng, Whitney , Mack, Joana M. , Tran, Andrew , Ogino, Jayme , Pearson, Erika , Bies, Joshua J., Smink, Gayle , Shah, Sonal D. , Mohney, Lindsey , Fassel, Hannah, Schulte, Rachael , Tessem, Renae A., Swaminathan, Neeraja , McLean, Thomas W. , Alturky, Sara , Wu, Melinda , Atkinson, Autumn, Al‐Huniti, Ahmad , Massey, Gita , Engel, Elissa , Echols, Tyson C. , Kumar, Sumukh Arun , Fox, Michael D. , King, Katherine A., Mack, Joana , Pearson, Erika , Shah, Sonal D , Swaminathan, Neeraja , McLean, Thomas W , Blatt, Julie , Massey, Gita , Ricci, Kiersten , Echols, Tyson , Fox, Michael , Sisk, Bryan A , Aye, Jamie M. , Chang, Vivian Y. , Hogeling, Marcia , Atkinson, Autumn

Mayo Clinic

Pediatric Blood & Cancer | March 17, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31661 | PMID 40091541 Get It

ABSTRACTPatients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Banerjee, Rahul , Richards, Alicia, Midha, Shonali , Afrough, Aimaz , Anwer, Faiz , Atanackovic, Djordje , Bachanová, Veronika , Bhurtel, Jenny , Cicero, Kara I. , Davis, James A. , Dhakal, Binod , Ferreri, Christopher J. , Forsberg, Peter A. , Freeman, Ciara L. , Khouri, Jack , Kumar, Anupama, Liu, Yuxin , Mikkilineni, Lekha , Peres, Lauren C. , Purvey, Sneha , Raza, Shahzad , Sborov, Douglas W. , Shune, Leyla , Wagner, Charlotte B , Zanwar, Saurabh , Sidana, Surbhi , Patel, Krina K. , Kumar, Shaji , Lin, Yi , Martin, Thomas G. , Voorhees, Peter M. , Anderson, Larry D. , Cowan, Andrew J., Chhabra, Saurabh , Davis, James A , Dhakal, Binod , Freeman, Ciara L , Herr, Megan M. , Jain, Tania , Khouri, Jack , Kocoglu, Mehmet H , McGuirk, Joseph , Parrondo, Ricardo D , Pasvolsky, Oren , Sborov, Douglas W , Wagner, Charlotte , Zanwar, Saurabh S , Sidana, Surbhi , Patel, Krina , Kumar, Shaji K , Voorhees, Peter , Anderson, Larry D , Kaur, Gurbakhash , Bachanova, Veronika , Banerjee, Rahul , Raza, Shahzad , Anwer, Faiz , Atrash, Shebli , Beitinjaneh, Amer , Puglianini, Omar Castañeda , Chhabra, Saurabh , Dima, Danai , Jain, Tania , Janakiram, Murali , Kocoglu, Mehmet H. , Locke, Frederick L. , McGuirk, Joseph P. , Nadeem, Omar , Pasvolsky, Oren , Reshef, Ran , Richard, Shambavi , Rossi, Adriana , Hansen, Doris K. , Kaur, Gurbakhash

Mayo Clinic

Blood Advances | March 15, 2025 | Volume: 9 | Issue: 9 | Pages: 2336-2340

10.1182/bloodadvances.2025016131 | PMID 40088469 Get It

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations
Shah, Meera , Hung, Kevin , Baranwal, Anmol , Al‐Kali, Aref , Toop, Carla , Greipp, Patricia T. , Brown, Anna , Shah, Syed Naseem, Khanna, Shreyas, Ladon, Dariusz, Gannamani, Vedavyas, Begna, Kebede H. , Price, Zoe, Rud, Danielle, Litzow, Mark R. , Bardy, Peter, Badar, Talha , Kumar, Sharad , Patnaik, Mrinal M. , Foran, James M. , He, Rong , Gangat, Naseema , Scott, Hamish S. , Mangaonkar, Abhishek A. , Hahn, Christopher N , Tefferi, Ayalew , Hiwase, Devendra , Shah, Mithun V , Kutyna, Monika M , Al-Kali, Aref , Toop, Carla , Greipp, Patricia T , Brown, Anna L , Begna, Kebede , Litzow, Mark R. , Hogan, William J , Badar, Talha , Kumar, Sharad , Patnaik, Mrinal , He, Rong , Gangat, Naseema , Scott, Hamish , Arana Yi, Cecilia , Hahn, Christopher , Arber, Daniel A , Kok, Chung H , Hiwase, Devendra , Baranwal, Anmol , Hung, Kevin , Kutyna, Monika , Chen, Dong , Price, Zoe K. , Hogan, William J. , Yeung, David , Yi, Cecilia Arana , Alkhateeb, Hassan B. , THOMAS, DANIEL W. , Orazi, Attilio , Arber, Daniel A. , Kok, Chung Hoow

Mayo Clinic

Blood Advances | March 14, 2025 | Volume: 9 | Issue: 13 | Pages: 3370-3380

10.1182/bloodadvances.2024015238 | PMID 40085954 Get It

Abstract This retrospective analysis aimed to provide evidence-based risk stratification of TP53-mutated (TP53mut) myeloid neoplasms (MNs). Of 580 MNs harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92 (15.9%), and 75 (12.9%) were classified as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) with low blasts (MDS-LB), MDS with excess blasts (MDS-EB)-2, and -EB1 according to the revised fourth edition of the World Health Organization (WHO) classification, respectively. Hierarchical analysis identified the following 4 risk groups with distinct survival: (1) MDS-LB, (2) MDS-EB1/EB2/AML VAF &lt;10%, (3) MDS-EB1/EB2 VAF ≥10%, and (4) AML VAF ≥10%. We next evaluated the impact of allelic status, VAF, and complex karyotype (CK). In our cohort, the significance of biallelic status was limited to MDS with &lt;5% blasts and not for blasts 5% to 9%, as proposed by the International Consensus Classification (ICC), or 5% to 19%, as proposed by the fifth edition of the WHO (WHO-5). MDS-EB1 and -EB2 with VAF ≥10% had comparable survival (9.6 vs 7.2 months; P = .12), regardless of allelic status. Contrary to the ICC proposal, MDS-EB1/EB2 with VAF &lt;10% and CK had poor survival compared with those without CK, comparable to MDS-EB1/EB2 with VAF ≥10% (5.6 vs 26.2 vs 6.3 months; P = .003). Survival of TP53mut AML was poor (median 3.9 months) regardless of allelic/CK status. Thus, using ICC or WHO-5 may underestimate prognosis of MDS with blasts 5% to 19% and 5% to 9%, respectively. Collectively, the hierarchical model acknowledges poor survival of 91.9% TP53mut MDS and AML compared with 36.5% and 80.7% by WHO-5 and ICC, respectively.
Clinical neurocardiology: defining the value of neuroscience‐based cardiovascular therapeutics – 2024 update
Aksu, Tolga , Arora, Rishi , Chen, Peng‐Sheng , Fudim, Marat , Herring, Neil , Po, Sunny S. , Stavrakis, Stavros , Somers, Virend K. , Tan, Alex Y. , Valderrábano, Miguel , Shivkumar, Kalyanam , Shivkumar, Kalyanam , Ajijola, Olujimi A. , Biaggioni, Italo , Ferrari, Gaetano Maria De , Dusi, Veronica , Goldberger, Jeffrey J , Green, Alexander L. , Khalsa, Sahib S. , Kumar, Rajesh , Lakatta, Edward G. , Mehra, Reena , Meyer, Christian , Somers, Virend K.

Mayo Clinic

The Journal of Physiology | March 12, 2025 | Volume: 603 | Issue: 7 | Pages: 1781-1839

10.1113/jp284741 | PMID 40056025 Get It

AbstractThe intricate role of the autonomic nervous system (ANS) in regulating cardiac physiology has long been recognized. Aberrant function of the ANS is central to the pathophysiology of cardiovascular diseases. It stands to reason, therefore, that neuroscience‐based cardiovascular therapeutics hold great promise in the treatment of cardiovascular diseases in humans. A decade after the inaugural edition, this White Paper reviews the current state of understanding of human cardiac neuroanatomy, neurophysiology and pathophysiology in specific disease conditions, autonomic testing, risk stratification, and neuromodulatory strategies to mitigate the progression of cardiovascular diseases. image
Proteomics of Extracellular Vesicles: Recent Updates, Challenges and Limitations
Singh, Mohini , Tiwari, Prashant Kumar , Kumar, Sanjay , Kumar, Sanjay , Singh, Mohini, Kashyap, Vivek Kumar

Mayo Clinic

Proteomes | March 4, 2025 | Volume: 13 | Issue: 1 | Pages: 12

10.3390/proteomes13010012 | PMID 40137841 Get It

Extracellular vesicles (EVs) are lipid-bound vesicles secreted by cells, including exosomes, microvesicles, and apoptotic bodies. Proteomic analyses of EVs, particularly in relation to cancer, reveal specific biomarkers crucial for diagnosis and therapy. However, isolation techniques such as ultracentrifugation, size-exclusion chromatography, and ultrafiltration face challenges regarding purity, contamination, and yield. Contamination from other proteins complicates downstream processing, leading to difficulties in identifying biomarkers and interpreting results. Future research will focus on refining EV characterization for diagnostic and therapeutic applications, improving proteomics tools for greater accuracy, and exploring the use of EVs in drug delivery and regenerative medicine. In this review, we provide a bird’s eye view of various challenges, starting with EV isolation methods, yield, purity, and limitations in the proteome analysis of EVs for identifying protein targets.
What’s Important (Arts and Humanities): Learning to Feel
Kumar, Sonal , Noland, Shelley S. , Noland, Shelley

Mayo Clinic

Journal of Bone and Joint Surgery | March 3, 2025 | Volume: 107 | Issue: 9 | Pages: 1022-1023

10.2106/jbjs.24.01454 | PMID 40029939 Get It

The profile and clinical predicting effect of non-rash dermatologic toxicity related to targeted therapy in stage-IV non-small cell lung cancer patients
Peng, Yanmei , Liu, Zhaoheng , Kumar, Ashok V., Gu, Zhong, Kosuru, Nikhila, Santos, Pedro Reck dos , D’Cunha, Jonathan, Ernani, Vinicius , Wampfler, Jason A. , Reck Dos Santos, Pedro A, D'Cunha, Jonathan, Santos, Pedro Augusto Reck Dos , Costello, Collin M. , Yang, Ping

Mayo Clinic

BioScience Trends | March 2, 2025 | Volume: 19 | Issue: 2 | Pages: 221-231

10.5582/bst.2024.01424 | PMID 40024684 Get It

Design, Implementation, and Evaluation of a Multidisciplinary Palliative Care Curriculum for Obstetrician Gynecologist Residents
Thannickal, Aneesa , Alston, Meredith , Amory, Josephine, Kumar, Amanika, Lefkowits, Carolyn , Brubaker, Lindsay W. , Moroney, Marisa R. , Kumar, Amanika

Mayo Clinic

Palliative Medicine Reports | February 28, 2025 | Volume: 6 | Issue: 1 | Pages: No page available

10.1089/pmr.2024.0082 | PMID 40171212 Get It

Purpose: Palliative care focuses on providing relief from the stress and symptoms of serious illness. Obstetrician gynecologists (OBGYNs) manage a variety of complex clinical situations ranging from delivering a cancer diagnosis to caring for a neonatal demise to symptom management, all of which fall within the realm of palliative care. Palliative care is relevant to the practice of OBGYNs, yet residents rarely receive formal primary palliative care training. We sought to design, implement, and evaluate a dedicated curriculum on palliative care for OBGYN residents. Methods: We performed a needs assessment of an OBGYN residency at a single institution. This information was used to develop a multidisciplinary palliative care curriculum. Post-curriculum surveys were distributed and analyzed. Descriptive statistics were utilized. Results: Our needs assessment identified a lack of knowledge and competency in palliative care concepts and skills. Using this information, we created a multidisciplinary palliative care curriculum, including clinical experiences, chalk talks, and online didactics. Post-curriculum surveys revealed a marked improvement in both knowledge base and perceived competence. Feedback was overwhelmingly positive; residents indicated that the curriculum was both a valuable use of time and would impact their provision of care in the future. Conclusion: A dedicated palliative care curriculum is an impactful addition to OBGYN training.